{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T22:23:56Z","timestamp":1788387836307,"version":"build-2803163510"},"reference-count":35,"publisher":"Impact Journals, LLC","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncotarget"],"published-print":{"date-parts":[[2023,4,26]]},"DOI":"10.18632\/oncotarget.28415","type":"journal-article","created":{"date-parts":[[2023,4,26]],"date-time":"2023-04-26T09:42:57Z","timestamp":1682502177000},"page":"384-394","source":"Crossref","is-referenced-by-count":45,"title":["Systemic AL amyloidosis: current approach and future direction"],"prefix":"10.18632","volume":"14","author":[{"given":"Maroun","family":"Bou Zerdan","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, SUNY Upstate Medical University, Syracuse, NY 13210, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lewis","family":"Nasr","sequence":"additional","affiliation":[{"name":"University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farhan","family":"Khalid","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Monmouth Medical Center, Long Branch, NJ 07740, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabine","family":"Allam","sequence":"additional","affiliation":[{"name":"Department of Medicine and Medical Sciences, University of Balamand, Balamand, Lebanon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youssef","family":"Bouferraa","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Cleveland Clinic, Cleveland, OH 44195, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saba","family":"Batool","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, UnityPoint Methodist, Peoria, IL 61636, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad","family":"Tayyeb","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Monmouth Medical Center, Long Branch, NJ 07740, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shubham","family":"Adroja","sequence":"additional","affiliation":[{"name":"Hematology and Medical Oncology, Houston Methodist Cancer Center, Houston, TX 77094, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahinbanu","family":"Mammadii","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, SUNY Upstate Medical University, Syracuse, NY 13210, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faiz","family":"Anwer","sequence":"additional","affiliation":[{"name":"Department of Hematology-Oncology, Cleveland Clinic, Cleveland, OH 44195, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahzad","family":"Raza","sequence":"additional","affiliation":[{"name":"Department of Hematology-Oncology, Cleveland Clinic, Cleveland, OH 44195, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chakra P.","family":"Chaulagain","sequence":"additional","affiliation":[{"name":"Department of Hematology-Oncology, Myeloma and Amyloidosis Program, Maroone Cancer Center, Cleveland Clinic Florida, Weston, FL 33331, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"7892","published-online":{"date-parts":[[2023,4,26]]},"reference":[{"key":"1","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1001\/jama.2020.5493","article-title":"Systemic Amyloidosis Recognition, Prognosis, and Therapy: A Systematic Review","volume":"32","author":"Dispenzieri","year":"2020","journal-title":"JAMA"},{"key":"2","doi-asserted-by":"publisher","first-page":"1546","DOI":"10.1016\/j.mayocp.2021.03.012","article-title":"Treatment of AL Amyloidosis: Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Statement 2020 Update","volume":"9","author":"Kapoor","year":"2021","journal-title":"Mayo Clin Proc"},{"key":"3","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.1093\/ndt\/gfy291","article-title":"AL amyloidosis: advances in diagnostics and treatment","volume":"3","author":"Ry\u0161av\u00e1","year":"2019","journal-title":"Nephrol Dial Transplant"},{"key":"4","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1111\/ejh.13681","article-title":"Impact of time to diagnosis on Mayo stages, treatment outcome, and survival in patients with AL amyloidosis and cardiac involvement","volume":"10","author":"Reinhardt","year":"2021","journal-title":"Eur J Haematol"},{"key":"5","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1002\/ajh.25819","article-title":"Immunoglobulin light chain amyloidosis: 2020 update on diagnosis, prognosis, and treatment","volume":"9","author":"Gertz","year":"2020","journal-title":"Am J Hematol"},{"key":"6","doi-asserted-by":"publisher","first-page":"147","DOI":"10.14740\/jh866","article-title":"Current Updates on the Management of AL Amyloidosis","volume":"1","author":"Raza","year":"2021","journal-title":"J Hematol"},{"key":"7","doi-asserted-by":"publisher","first-page":"907584","DOI":"10.3389\/fonc.2022.907584","article-title":"Supportive Care and Symptom Management for Patients With Immunoglobulin Light Chain (AL) Amyloidosis","volume":"1","author":"Tuchman","year":"2022","journal-title":"Front Oncol"},{"key":"8","doi-asserted-by":"publisher","first-page":"232","DOI":"10.4065\/mcp.2009.0547","article-title":"Clinical features and treatment response of light chain (AL) amyloidosis diagnosed in patients with previous diagnosis of multiple myeloma","volume":"8","author":"Kumar","year":"2010","journal-title":"Mayo Clin Proc"},{"key":"9","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1002\/clc.23572","article-title":"Cardiac amyloidosis-A review of current literature for the practicing physician","volume":"4","author":"Jain","year":"2021","journal-title":"Clin Cardiol"},{"key":"10","doi-asserted-by":"publisher","first-page":"2047","DOI":"10.1161\/CIRCULATIONAHA.104.489187","article-title":"Diagnosis and management of the cardiac amyloidoses","volume":"11","author":"Falk","year":"2005","journal-title":"Circulation"},{"key":"11","doi-asserted-by":"publisher","first-page":"e7","DOI":"10.1161\/CIR.0000000000000792","article-title":"Cardiac Amyloidosis: Evolving Diagnosis and Management: A Scientific Statement From the American Heart Association","volume":"14","author":"Ruberg","year":"2020","journal-title":"Circulation"},{"key":"12","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/j.jaccao.2020.05.012","article-title":"Incremental Value of Global Longitudinal Strain for Predicting Survival in Patients With Advanced AL Amyloidosis","volume":"2","author":"Liu","year":"2020","journal-title":"JACC CardioOncol"},{"key":"13","doi-asserted-by":"publisher","first-page":"1979","DOI":"10.1038\/leu.2016.191","article-title":"Rationale, application and clinical qualification for NT-proBNP as a surrogate end point in pivotal clinical trials in patients with AL amyloidosis","volume":"3","author":"Comenzo","year":"2016","journal-title":"Leukemia"},{"key":"14","doi-asserted-by":"publisher","first-page":"27","DOI":"10.14797\/mdcvj.1070","article-title":"Light Chain Amyloidosis: Epidemiology, Staging, and Prognostication","volume":"1","author":"Baker","year":"2022","journal-title":"Methodist Debakey Cardiovasc J"},{"key":"15","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1159\/000518948","article-title":"Primary Localized Cutaneous Amyloidosis: A Retrospective Study of an Uncommon Skin Disease in the Largest Tertiary Care Center in Switzerland","volume":"23","author":"Kolm","year":"2022","journal-title":"Dermatology"},{"key":"16","doi-asserted-by":"publisher","first-page":"101967","DOI":"10.1016\/j.eucr.2021.101967","article-title":"Primary localized amyloidosis of the ureter with osseous metaplasia presenting as a suspicious ureteral mass","volume":"4","author":"Parwani","year":"2022","journal-title":"Urol Case Rep"},{"key":"17","doi-asserted-by":"publisher","first-page":"425","DOI":"10.4103\/idoj.idoj_405_21","article-title":"Localized Amyloidosis of Palate","volume":"1","author":"Banerjee","year":"2022","journal-title":"Indian Dermatol Online J"},{"key":"18","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.3748\/wjg.v27.i12.1132","article-title":"Primary localized gastric amyloidosis: A scoping review of the literature from clinical presentations to prognosis","volume":"2","author":"Chang","year":"2021","journal-title":"World J Gastroenterol"},{"key":"19","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1056\/NEJMoa1709974","article-title":"Long-Term Follow-up of Monoclonal Gammopathy of Undetermined Significance","volume":"37","author":"Rajkumar","year":"2018","journal-title":"N Engl J Med"},{"key":"20","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1007\/s00428-022-03431-3","article-title":"Plasma cell neoplasms and related entities-evolution in diagnosis and classification","volume":"48","author":"Cook","year":"2023","journal-title":"Virchows Arch"},{"key":"21","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1080\/17474086.2022.2115353","article-title":"Recent guidelines for high-dose chemotherapy and autologous stem cell transplant for systemic AL amyloidosis: a practitioner\u2019s perspective","volume":"1","author":"Wechalekar","year":"2022","journal-title":"Expert Rev Hematol"},{"key":"22","doi-asserted-by":"publisher","first-page":"2620","DOI":"10.1182\/blood.2020006913","article-title":"Management of AL amyloidosis in 2020","volume":"13","author":"Merlini","year":"2020","journal-title":"Blood"},{"key":"23","doi-asserted-by":"publisher","first-page":"2157","DOI":"10.1016\/j.bbmt.2018.06.017","article-title":"Autologous Stem Cell Transplant for Immunoglobulin Light Chain Amyloidosis Patients Aged 70 to 75","volume":"2","author":"Hogan","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"key":"24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/13506129.2021.2002841","article-title":"Guidelines for high dose chemotherapy and stem cell transplantation for systemic AL amyloidosis: EHA-ISA working group guidelines","volume":"2","author":"Palladini","year":"2022","journal-title":"Amyloid"},{"key":"25","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1038\/bmt.2017.68","article-title":"Revisiting conditioning dose in newly diagnosed light chain amyloidosis undergoing frontline autologous stem cell transplant: impact on response and survival","volume":"5","author":"Kourelis","year":"2017","journal-title":"Bone Marrow Transplant"},{"key":"26","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1111\/j.1365-2141.2006.06204.x","article-title":"Outcome of autologous stem cell transplantation for AL amyloidosis in the UK","volume":"13","author":"Hawkins","year":"2006","journal-title":"Br J Haematol"},{"key":"27","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1046\/j.1365-2141.1998.00772.x","article-title":"Prognostic factors for survival and response after high-dose therapy and autologous stem cell transplantation in systemic AL amyloidosis: a report on 21 patients","volume":"10","author":"Bataille","year":"1998","journal-title":"Br J Haematol"},{"key":"28","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1093\/ndt\/gfab189","article-title":"Predictors and outcomes of acute kidney injury during autologous stem cell transplantation in AL amyloidosis","volume":"3","author":"Havasi","year":"2022","journal-title":"Nephrol Dial Transplant"},{"key":"29","doi-asserted-by":"publisher","first-page":"2271","DOI":"10.1182\/blood.2019000834","article-title":"A prospective observational study of 915 patients with systemic AL amyloidosis treated with upfront bortezomib","volume":"13","author":"Wechalekar","year":"2019","journal-title":"Blood"},{"key":"30","doi-asserted-by":"publisher","first-page":"3252","DOI":"10.1200\/JCO.20.01285","article-title":"Bortezomib, Melphalan, and Dexamethasone for Light-Chain Amyloidosis","volume":"3","author":"Nicolas-Virelizier","year":"2020","journal-title":"J Clin Oncol"},{"key":"31","doi-asserted-by":"publisher","first-page":"1601","DOI":"10.3389\/fphar.2019.01601","article-title":"Efficacy of Chemotherapies and Stem Cell Transplantation for Systemic AL Amyloidosis: A Network Meta-Analysis","volume":"1","author":"Xu","year":"2019","journal-title":"Front Pharmacol"},{"key":"32","doi-asserted-by":"publisher","first-page":"4346","DOI":"10.1182\/blood-2011-01-330738","article-title":"Outcome of AL amyloidosis after high-dose melphalan and autologous stem cell transplantation: long-term results in a series of 421 patients","volume":"11","author":"Doros","year":"2011","journal-title":"Blood"},{"key":"33","doi-asserted-by":"publisher","first-page":"743","DOI":"10.3324\/haematol.2013.095463","article-title":"Oral melphalan and dexamethasone grants extended survival with minimal toxicity in AL amyloidosis: long-term results of a risk-adapted approach","volume":"9","author":"Merlini","year":"2014","journal-title":"Haematologica"},{"key":"34","doi-asserted-by":"publisher","first-page":"789","DOI":"10.3324\/haematol.2012.075192","article-title":"Melphalan, lenalidomide and dexamethasone for the treatment of immunoglobulin light chain amyloidosis: results of a phase II trial","volume":"9","author":"Seldin","year":"2013","journal-title":"Haematologica"},{"key":"35","doi-asserted-by":"publisher","first-page":"2632","DOI":"10.1182\/blood.2020009039","article-title":"Phase 1a\/b study of monoclonal antibody CAEL-101 (11-1F4) in patients with AL amyloidosis","volume":"13","author":"Eisenberger","year":"2021","journal-title":"Blood"}],"container-title":["Oncotarget"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.28415","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,26]],"date-time":"2023-04-26T09:43:18Z","timestamp":1682502198000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.28415"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,26]]},"references-count":35,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,4,26]]}},"alternative-id":["28415"],"URL":"https:\/\/doi.org\/10.18632\/oncotarget.28415","relation":{},"ISSN":["1949-2553"],"issn-type":[{"value":"1949-2553","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,26]]}}}